Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
Takeo Hata,1 Atsushi Hirata,2 Ryosuke Ota,2 Keiko Hosohata,3 Masami Nishihara,1 Masashi Neo,1 Takahiro Katsumata1 1Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan; 2Department of Pharmacy, Kindai University Nara Hospital, Ikoma, Nara, Japan; 3Edu...
Main Authors: | Hata T, Hirata A, Ota R, Hosohata K, Nishihara M, Neo M, Katsumata T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-08-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/biologic-disease-modifying-and-other-anti-rheumatic-drugs-use-in-patie-peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis
by: Marshall A, et al.
Published: (2019-05-01) -
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
by: Kemper Alex R, et al.
Published: (2012-03-01) -
Comparison of the efficacy and safety of methotrexate alone or in combination with leflunomide in the treatment of juvenile idiopathic arthritis: a double-blind, placebo-controlled, randomized trial
by: Zahra Rezaieyazdi, et al.
Published: (2023-03-01) -
Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study
by: Violetta Opoka-Winiarska, et al.
Published: (2021-04-01) -
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
by: Clara Malattia, et al.
Published: (2020-09-01)